Guide
What Is a Lateral Flow Uncut Sheet? From Assay Development to OEM Manufacturing
Learn what a lateral flow uncut sheet is, how it is manufactured, and what IVD developers should evaluate when selecting an uncut sheet OEM partner.
In lateral flow manufacturing, an uncut sheet generally refers to a semi-finished assay card or laminated sheet that has completed key reagent-deposition and assembly steps but has not yet been converted into individual test strips and finished devices.
For IVD manufacturers, sourcing an uncut sheet can shift part of the technically demanding assay-development and strip-manufacturing process to an upstream supplier while allowing downstream cutting, cassette assembly, packaging and commercialization to be managed according to the customer's own manufacturing model.
However, “uncut sheet” is an industry term rather than a universal specification. The exact materials, reagents and processing included in an uncut-sheet supply should always be defined between supplier and customer.
1
Semi-finished assay platform
Critical membranes, pads and assay reagents may already be assembled into a card before individual strips are cut.
2
More than raw materials
An uncut sheet incorporates part of the assay formulation and manufacturing process, not just individual membranes or antibodies.
3
Still requires validation
Cutting, cassette design, packaging, storage and final-device configuration can still affect performance and should be verified.
1. What Exactly Is a Lateral Flow Uncut Sheet?
A conventional lateral flow strip is constructed from several overlapping functional materials mounted on a backing support. These commonly include a sample pad, conjugate pad, nitrocellulose membrane and absorbent pad.[1–3]
Capture reagents are immobilized on defined regions of the analytical membrane to form the test and control lines, while labeled detection reagents are commonly dried onto a conjugate-release pad.
During manufacturing, these materials can be treated, dried and laminated together as a larger card or sheet before being slit or cut into narrow individual test strips.[3,4]
Working definition used in this article
“Uncut sheet” refers to a semi-finished lateral flow assembly supplied before final strip cutting and device assembly. The exact configuration can differ between products and suppliers, so the bill of materials and supplied processing stage should be confirmed for each project.
2. What Can Be Included in an Uncut Sheet?
There is no single configuration that applies to every lateral flow product. Depending on the assay and OEM arrangement, an uncut sheet may incorporate several processed components.
| Component | Typical Function | Possible Processing Before Supply |
|---|---|---|
| Sample Pad | Receives the specimen and supports controlled transfer into the assay. | Material selection, pretreatment and drying where required. |
| Conjugate Pad | Stores the labeled detection reagent in a dry state and releases it when the test runs. | Pad pretreatment, conjugate dispensing and controlled drying. |
| Nitrocellulose Membrane | Provides the analytical reaction zone and capillary pathway. | Test-line and control-line reagent dispensing followed by drying. |
| Absorbent Pad | Supports continued capillary flow and receives fluid after it passes the reaction zone. | Material sizing and integration into the laminated card. |
| Backing Card | Provides mechanical support and maintains the position and overlap of strip components. | Lamination of processed membrane and pad materials. |
The precise construction should always be confirmed in the product specification. For example, one OEM project may receive a fully laminated card containing treated sample and conjugate pads, while another may intentionally leave selected downstream materials to the customer.
3. Where Does the Uncut Sheet Sit in the Manufacturing Process?
The easiest way to understand an uncut sheet is to look at the complete lateral flow manufacturing chain.
Raw Materials
→
Assay Development
→
Reagent Dispensing
→
Drying & Pad Treatment
→
Lamination
→
Uncut Sheet
→
Strip Cutting
→
Cassette Assembly
→
Finished Test
Published descriptions of lateral flow manufacturing similarly identify reagent dispensing, drying, assembly or lamination, cutting and cassette assembly as distinct processing stages.[3,4]
4. Assay Development Comes Before Scale-Up
An uncut sheet should not be viewed simply as a collection of materials laminated together.
Before stable manufacturing can begin, the assay itself usually requires optimization of biological reagents, reporter conjugates, membrane selection, pad materials, buffers and strip geometry.
These factors interact. Changing one component can alter signal intensity, background, flow rate or release characteristics.[2,5]
Typical development variables include
- Capture and detection antibody pair
- Test-line and control-line concentrations
- Reporter particle and conjugation chemistry
- Conjugate-pad loading and release behavior
- Nitrocellulose membrane flow characteristics
- Sample-pad treatment
- Running-buffer composition
- Component overlap and strip geometry
- Sample volume and assay run time
Moving into manufacturing before these variables are sufficiently controlled can turn development variation into production variation.
5. Reagent Dispensing and Drying
One of the defining manufacturing stages is the controlled deposition of biological reagents.
Test and control reagents are typically dispensed onto defined positions of the analytical membrane. The labeled recognition reagent is separately applied to or incorporated into the conjugate pad. The processed materials are then dried under controlled conditions before assembly.[3,4]
These steps matter because the assay must later rehydrate and mobilize the dried reagents while maintaining biological activity.
Dispensing consistency
Variation in reagent deposition can affect the amount of active material available at the test line or conjugate pad.
During scale-up, equipment parameters such as dispensing rate, line position and process repeatability therefore become part of assay performance control.
Drying conditions
Drying is not simply a waiting period between manufacturing steps. Reagent stability and subsequent rehydration behavior may depend on formulation and drying conditions.
The optimized process should consequently be transferred together with the reagent formulation rather than assuming that any drying condition will produce equivalent performance.
6. Lamination: Turning Components into a Functional Flow Path
During lamination, processed pads and membrane materials are positioned on a backing card to form a continuous fluidic pathway.
Adjacent components typically overlap so that the sample can move continuously from the sample application area through the conjugate zone and analytical membrane toward the absorbent pad.[1,3]
This means lamination accuracy can influence more than the physical appearance of the card.
Why overlap matters
Poor or inconsistent contact between adjacent materials can alter liquid transfer. For this reason, pad position, overlap and alignment should be treated as controlled manufacturing parameters.
7. What Happens After the Uncut Sheet Is Supplied?
In a typical uncut-sheet model, the customer or downstream manufacturing partner converts the larger card into individual tests.
Cut the sheet into strips
The laminated card is slit or cut to the strip width defined for the product design.
Insert the strip into the cassette
The strip is positioned inside the intended housing so that the sample well, membrane and result window align correctly.
Complete accessory configuration
Depending on the product, buffers, droppers, collection devices or other accessories may be assembled with the test.
Package the finished device
Packaging conditions should protect the test against relevant environmental factors during its established shelf life.
Perform final quality checks
The finished configuration should be evaluated against defined release criteria before distribution.
Published descriptions of LFIA production distinguish laminated-sheet manufacturing from strip cutting and cassette assembly, which is why the uncut-sheet model can be useful for companies that already possess downstream conversion and packaging capability.[4]
8. Why Can Cutting and Cassette Assembly Still Affect Performance?
Receiving a validated uncut sheet does not mean that downstream manufacturing variables can be ignored.
Strip width influences the effective volume of membrane and reagent available in each test. Cutting quality can affect the physical edge of the membrane, while cassette geometry and pressure points can influence contact between strip components and the way liquid travels through the assembled device.
The final device therefore needs to be evaluated in its actual housing rather than assuming that performance observed on an open strip will automatically remain unchanged.
Practical rule
Treat the uncut sheet as a validated semi-finished input — not as a substitute for verification of the final assembled rapid test.
9. Uncut Sheet vs. Individual Raw-Material Sourcing
Both sourcing strategies can be appropriate. The choice depends largely on a manufacturer's technical capabilities, desired level of process ownership and commercialization strategy.
| Model | Customer Receives | Customer Usually Controls | Best Suited To |
|---|---|---|---|
| Raw-Material Sourcing | Antibodies, antigens, membranes, pads or reporter components | Assay formulation, conjugation, dispensing, lamination and downstream manufacturing | Developers with established internal LFIA R&D and production capability |
| Uncut Sheet | A defined semi-finished laminated assay configuration | Cutting, final housing, packaging and other agreed downstream operations | Manufacturers seeking to reduce upstream assay and membrane-processing workload |
| Finished-Test OEM | A finished or near-finished configured rapid test according to the project scope | Branding, market-specific activities and responsibilities defined in the OEM agreement | Organizations requiring a broader outsourced manufacturing solution |
These categories are commercial models rather than universal regulatory classifications. The actual division of responsibilities should be documented clearly for each project.
10. What Should You Confirm with an Uncut Sheet OEM Supplier?
Price and product name alone provide very little information about whether two uncut-sheet supplies are technically equivalent.
Before moving into qualification or scale-up, the customer should understand both the supplied assay configuration and the associated manufacturing controls.
Recommended OEM qualification questions
- Which pads and membranes are included in the supplied sheet?
- Are the test and control reagents already dispensed?
- Is the labeled conjugate incorporated into the supplied assembly?
- What strip width and cutting tolerances are recommended?
- What cassette dimensions and pressure geometry were used during validation?
- Which sample type and running buffer were used?
- What analytical performance criteria are used for lot release?
- How are critical raw-material lot changes controlled?
- What storage conditions are specified for the uncut sheet?
- What stability data are available for the supplied configuration?
- How should transport conditions be controlled?
- What documentation accompanies each production lot?
11. From Prototype to OEM Manufacturing
A successful laboratory prototype is not automatically a manufacturing-ready product.
Scale-up requires conversion of experimental procedures into controlled and repeatable processes. This may involve equipment-specific dispensing parameters, defined drying conditions, material tolerances, lamination settings, cutting specifications and in-process quality controls.[4,5]
Historical and contemporary LFIA manufacturing literature has repeatedly identified test-to-test variability as an important challenge, which makes process control particularly relevant when moving from manual development into volume production.[3]
Confirm the assay principle
Establish the target, assay architecture and intended specimen type.
Screen and optimize biological reagents
Select appropriate antibody or antigen systems and confirm functional pair performance.
Optimize strip materials
Select membranes, pads, conjugate systems and buffers as an integrated flow platform.
Establish pilot manufacturing parameters
Transfer dispensing, drying and lamination conditions into repeatable production procedures.
Evaluate pilot lots
Compare analytical performance and manufacturing consistency across representative production runs.
Define the uncut-sheet specification
Document dimensions, supplied components, storage conditions and agreed release criteria.
Validate the downstream configuration
Confirm cutting, cassette assembly and packaging using the intended finished-device design.
12. Quality Management Still Matters in an OEM Model
Outsourcing part of manufacturing does not remove the need for clear quality responsibilities.
ISO 13485:2016 provides an internationally recognized quality-management framework for organizations involved in medical-device design and production, including relevant suppliers and external parties.[6]
Quality agreements and technical specifications should therefore clearly define areas such as document control, approved materials, manufacturing changes, lot identification, nonconforming product and complaint or investigation responsibilities where applicable.
Regulatory scope depends on the final product and market
An uncut sheet is part of a manufacturing supply chain. Regulatory responsibilities for the final IVD depend on the finished product, intended use, target market and the roles of the organizations involved. These responsibilities should be evaluated separately from the commercial term “OEM.”
13. What Makes a Good Uncut Sheet?
A good uncut sheet is not simply one that produces a visible test line.
It should provide a controlled platform that can be converted into finished strips without introducing unacceptable variation.
| Area | What to Evaluate |
|---|---|
| Analytical Performance | Positive/negative discrimination, sensitivity, specificity and relevant analytical range |
| Flow Behavior | Consistent migration, appropriate run time and complete conjugate release |
| Physical Assembly | Alignment, pad overlap, membrane integrity and dimensional consistency |
| Reproducibility | Sheet-to-sheet, lot-to-lot and strip-to-strip performance |
| Conversion Compatibility | Reliable cutting and fit with the intended cassette design |
| Stability | Performance under defined storage and transport conditions |
Key Takeaway
A lateral flow uncut sheet is best understood as a semi-finished assay platform positioned between LFIA manufacturing and final device conversion.
It can integrate critical development and production stages such as reagent deposition, conjugate preparation, drying and lamination, while leaving strip cutting, cassette assembly and other downstream operations to the customer or manufacturing partner.
The value of an uncut-sheet OEM model depends not only on the biological assay, but also on manufacturing consistency, clearly defined specifications, downstream compatibility and quality control across the complete supply chain.
Looking for a Rapid Test Uncut Sheet Solution?
EXIMIO provides rapid-test uncut sheets and lateral flow development support for IVD manufacturers, from antibodies and antigens to assay optimization and semi-finished manufacturing solutions.
References
- Koczula KM, Gallotta A. Lateral flow assays. Essays in Biochemistry. 2016;60(1):111–120. DOI: 10.1042/EBC20150012. PMID: 27365041.
- Hsieh HV, Dantzler JL, Weigl BH. Analytical Tools to Improve Optimization Procedures for Lateral Flow Assays. Diagnostics. 2017;7(2):29. DOI: 10.3390/diagnostics7020029. PMID: 28555034.
- O'Farrell B. Evolution in Lateral Flow-Based Immunoassay Systems. In: Wong RC, Tse HY, editors. Lateral Flow Immunoassay. Humana Press; 2009. DOI: 10.1007/978-1-59745-240-3_1.
- Preechakasedkit P, Osotprasit S, et al. Lateral flow immunoassay for small-molecules detection in phytoproducts: a review. Journal of Natural Medicines. 2022. DOI: 10.1007/s11418-022-01605-6.
- Sukumaran A, Thomas T, Thomas R, Thomas RE, Paul JK, Vasudevan DM. Development and Troubleshooting in Lateral Flow Immunochromatography Assays. Indian Journal of Clinical Biochemistry. 2021;36(2):208–212. DOI: 10.1007/s12291-020-00887-5. PMID: 33867712.
- International Organization for Standardization. ISO 13485:2016 — Medical devices — Quality management systems — Requirements for regulatory purposes. ISO; 2016.